Pediatric Dermatology News
- Paradoxical Eczema Risk Low With Biologic Psoriasis Tx
- Reducing CVD Morbidity and Mortality in Psoriasis and PsA
- How Does Lebrikizumab Perform Across Different Subgroups?
- Disease Control Elusive for Many Patients on AD Therapies
- Acne in Primary Care: The Best of Times?
- Acne Stigma Persists Across Social and Professional Settings
- Bimekizumab Promising for Palmoplantar Pustular Psoriasis
- Tape Strips Detect Hidradenitis Suppurativa Biomarkers
- Patients With hEDS Report Skin Laxity, Scarring
- How Can Dermatologists Improve Cancer Care?
- Hope Emerges for Patients With Rare Skin Disorder
- MSWS 2023 What's New in Acne Treatment?
- MSWS 2023 Misdiagnoses Among Challenges in Managing Cutaneous Lymphoma
- EADV 2023 Novel Subcutaneous Biologics Show Promise in AD
- Meta-Analysis: Suicide Risk Not Increased With Isotretinoin
- Tapinarof Effective for AD in Patients as Young as 2 years
- EADV 2023 At 52 Weeks, Hair Growth Still Climbing on Deuruxolitinib
- Parent Concerns a Factor When Treating Patients With AD
- Questionnaire Measures Patient Satisfaction With Acne Tx
- Lebrikizumab Gets the Nod in the EU for Atopic Dermatitis
- EADV 2023 Vitiligo: 'Impressive' Results for Povorcitinib, Baricitinib
- EADV 2023 Topical Ivermectin Study Sheds Light on Dysbiosis in Rosacea
- CV, VTE Risk Not Seen in Derm Studies of JAK Inhibitors
- EADV 2023 Study Finds Ruxolitinib Effective, Safe for Children With AD
- Study Spotlights Features of Infantile Hemangioma Subset
- Dupilumab-Associated Lymphoid Reactions Require Caution
- Multicenter HS Study Expanding to More Clinical Sites
- Acne: Study Evaluates the Evidence for Nutraceuticals
- EADV 2023 Nemolizumab Promise for Prurigo Nodularis Continues
- GW Teledermatology Model Expands to Four Underserved Areas
- Bullying More Prevalent Among Adolescents With AD